Department of Health Economics, Corvinus University of Budapest, Fovam ter 8., H-1093 Budapest, Hungary.
CERGE-EI Fellow, Semmelweis University, Korányi S. 2/A, H-1083 Budapest, Hungary.
Curr Med Chem. 2019;26(2):259-269. doi: 10.2174/0929867324666170406112304.
Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians' and patients' skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.
生物制剂彻底改变了炎症性肠病（IBD）的治疗方法，如克罗恩病和溃疡性结肠炎。然而，由于高昂的成本和预算影响，并非所有符合临床条件的患者都能获得生物制剂。生物类似药在临床疗效和安全性方面与原研药高度相似。生物类似药的价格比参照产品低 15-75%，这使得它们成为一种更具成本效益的替代方案，并有望让更多的患者获得生物制剂治疗。预计总体节省的成本非常可观。如果实现的预算节省用于覆盖更多的生物治疗，那么可以治疗更多的额外 IBD 患者。目前，增加生物类似药使用的主要障碍是主要利益相关者的激励措施很少，而医生和患者对生物类似药的怀疑似乎正在改变。在未来几年，生物类似药预计将在 IBD 治疗中变得越来越重要，有助于改善治疗的可及性，提高人群健康获益和医疗系统的可持续性。这篇综述总结了生物类似药在 IBD 中的经济考虑因素以及生物类似物英夫利昔单抗在 IBD 治疗中的作用的文献结果。
